Kura Oncology KURA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's additional paid-in capital?
- Kura Oncology (KURA) reported additional paid-in capital of $1.36B in Q1 2026.
- How has Kura Oncology's additional paid-in capital changed year-over-year?
- Kura Oncology's additional paid-in capital increased by 3.0% year-over-year, from $1.32B to $1.36B.
- What is the long-term trend for Kura Oncology's additional paid-in capital?
- Over 5 years (2020 to 2025), Kura Oncology's additional paid-in capital has grown at a 8.1% compound annual growth rate (CAGR), from $913.35M to $1.35B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.